Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America News Hub.
Press releases published on June 24, 2025
フォートリア (Fortrea) とエメリー・ファーマ (Emery Pharma)、リファンピンを用いたFDA準拠の薬物相互作用 (Drug-Drug-Interaction、DDI) 試験を提供するための戦略的提携を発表
GlobeNewswire
·
June 24, 2025
ノースカロライナ州ダーラム発, June 24, 2025 (GLOBE NEWSWIRE) -- グローバルな大手医薬品開発業務受託機関 (CRO) であるフォートリア (NASDAQ: FTRE)(以下「同社」) は本日、大手分析・バイオ分析CROとしてcGMPおよびGLPに準拠した試験サービスを提供するエメリー・ファーマとの戦略的提携を発表した。この提携により、薬物相互作用 (DDI) 試験で使用される主要薬剤であるリファンピンに対し、1-メチル-4-ニトロソピペラジン (MNP) …
Fortrea 與 Emery Pharma 宣佈開展戰略合作，使用利福平 (Rifampin) 開展符合 FDA 要求的藥物相互作用試驗
GlobeNewswire
·
June 24, 2025
達勒姆，北卡羅來納州, June 24, 2025 (GLOBE NEWSWIRE) -- 全球領先的受託研究機構 (CRO) Fortrea (Nasdaq: FTRE)（下稱「公司」）今天宣佈與 Emery Pharma 建立戰略合作關係。Emery Pharma 是一家領先的分析和生物分析受託研究機構，根據現行的《良好生產規範》(cGMP) 和《藥物非臨床研究品質管理規範》(GLP) 提供測試服務。Fortrea 與 Emery Pharma 的戰略合作將為藥物相互作用 (DDI) …
Fortrea, Emery Pharma와 협력해 FDA 기준에 맞춰 리팜핀 사용 가능한 DDI 연구 지원
GlobeNewswire
·
June 24, 2025
노스캐롤라이나주 더럼, June 24, 2025 (GLOBE NEWSWIRE) -- 글로벌 임상시험수탁기관(CRO) Fortrea(나스닥명: FTRE)(이하 “회사”)가 Emery Pharma와 전략적 협력을 발표했다. Emery Pharma는 현행우수제조관리기준(cGMP)과 우수실험실운영기준(GLP)에 맞춰 테스트 서비스를 제공하며 업계를 선도하는 분석 및 생체시료 분석 CRO로, 약물상호작용(DDI) 연구에서 선호되는 리팜핀을 대상으로 로트별 1-메틸 …
Fortrea และ Emery Pharma ประกาศความร่วมมือเชิงกลยุทธ์เพื่อดำเนินการศึกษาวิจัยอันตรกิริยาระหว่างยาที่สอดคล้องกับ FDA โดยใช้ยาไรแฟมปิน (Rifampin…
GlobeNewswire
·
June 24, 2025
เดอร์แฮม, รัฐนอร์ทแคโรไลนา, June 24, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (“บริษัท”) ซึ่งเป็นองค์กรวิจัยตามสัญญา (Contract Research Organization, CRO) ทางคลินิกชั้นนำระดับโลก ได้ประกาศวันนี้ถึงความร่วมมือเชิงกลยุทธ์กับ Emery Pharma ซึ่งเป็น CRO …
Fortrea 与 Emery Pharma 宣布战略合作以开展符合 FDA 规范的利福平药物相互作用研究
GlobeNewswire
·
June 24, 2025
北卡罗来纳州达勒姆, June 24, 2025 (GLOBE NEWSWIRE) -- Fortrea（纳斯达克代码：FTRE，以下简称“公司”）是一家全球领先的合同研究组织（CRO），今日宣布与分析及生物分析领域领先的合同研究组织 Emery Pharma 建立战略合作。Emery Pharma 提供符合现行良好生产规范（cGMP）和良好实验室规范（GLP）的检测服务。该合作将为药物相互作用（DDI）研究中的首选药物利福平快速按批次进行1-甲基-4-亚硝基哌嗪（MNP …
BioAdaptives Announces National Launch of Pawpa™ Regen
GlobeNewswire
·
June 24, 2025
LAS VEGAS , June 24, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC Pink: BDPT), an innovator in nutraceutical and wellness science, today announces the upcoming national release of Pawpa™ Regen, a proprietary canine supplement that supports …
CrocCoin Introduces Groundbreaking Meme-to-DeFi Ecosystem on Solana, Featuring Progressive Decentralization
GlobeNewswire
·
June 24, 2025
Goiânia–GO,Brazil, June 24, 2025 (GLOBE NEWSWIRE) -- CrocCoin ($CROC), a pioneering cryptocurrency project built on the Solana blockchain, today announced the official launch of its comprehensive ecosystem. This platform redefines traditional meme token …
inCruises Breakthrough Year Continues with Record-Setting Revenue and Activations
GlobeNewswire
·
June 24, 2025
GUAYNABO, Puerto Rico, June 24, 2025 (GLOBE NEWSWIRE) -- inCruises, the world’s most valuable subscription-based travel rewards club, is pleased to announce that total revenue for May surpassed $31 million—the latest milestone in a sustained, record- …
First Atlantic Nickel Reports 366 Meters of 1.46% Nickel in Magnetic Concentrate From Third RPM Zone Step-Out Drill Hole, Opening Eastern Expansion Discovery Potential
GlobeNewswire
·
June 24, 2025
GRAND FALLS-WINDSOR, Newfoundland and Labrador, June 24, 2025 (GLOBE NEWSWIRE) -- First Atlantic Nickel Corp. (TSXV: FAN) (OTCQB: FANCF) (FSE: P21) ("First Atlantic" or the "Company") is pleased to announce positive Davis Tube Recovery (DTR) metallurgical …
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome
GlobeNewswire
·
June 24, 2025
ASHBURN, Va., June 24, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug …
Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation
GlobeNewswire
·
June 24, 2025
--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study; on average, enobosarm 3mg significantly reduced body …
The United Mexican States Announces Tender Results
GlobeNewswire
·
June 24, 2025
MEXICO CITY, June 24, 2025 (GLOBE NEWSWIRE) -- The United Mexican States (“Mexico”) previously announced an offer to purchase for cash (the “Tender Offer”) its outstanding notes of the series set forth in the tables below (collectively, the “Old Notes”), …
Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics
GlobeNewswire
·
June 24, 2025
Vancouver, Canada, June 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to …
SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes
GlobeNewswire
·
June 24, 2025
NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, …
Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference
GlobeNewswire
·
June 24, 2025
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the …
MindRank Announces Positive Phase 2b Results for AI-Designed Oral GLP-1 Receptor Agonist MDR-001 in Adults with Obesity or Overweight
GlobeNewswire
·
June 24, 2025
MDR-001 achieved statistically significant weight reductions of 8.2% to 10.3% at 24 weeks compared to 2.5% with placebo (p<0.00001), with up to 48.1% of participants achieving ≥10% weight loss. No treatment-related serious adverse events were reported. …
Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics
GlobeNewswire
·
June 24, 2025
Up to $40 Million Private Equity Financing into a New Entity Addressing Cardiac Genetic Diseases that Existing AAV Platforms are Unable to Treat Lexeo Contributing Expertise and Know-How in Cardiac Genetic Medicines, Preclinical Intellectual Property, and …
Bitget jetzt aktiv auf dem Sahyog-Portal von I4C zur Unterstützung der indischen Strafverfolgung
GlobeNewswire
·
June 24, 2025
NEU-DELHI, June 24, 2025 (GLOBE NEWSWIRE) -- Bitget, eine führende Kryptowährungsbörse und Web3-Firma, ist ab sofort offiziell auf Indiens Sahyog-Portal präsent. Dieses Portal ist eine zentrale Schnittstelle des Indian Cyber Crime Coordination Centre (I4C …
Bitget se une al portal Sahyog de I4C en la India para apoyar a las fuerzas del orden locales
GlobeNewswire
·
June 24, 2025
NUEVA DELHI, June 24, 2025 (GLOBE NEWSWIRE) -- Bitget, la principal bolsa de criptomonedas y empresa Web3, se ha incorporado oficialmente al portal Sahyog de la India, una interfaz clave dentro del marco del Centro de Coordinación de Delitos Cibernéticos …
Bitget rejoint le portail Sahyog de l’I4C indien pour soutenir les forces de l’ordre locales
GlobeNewswire
·
June 24, 2025
NEW DELHI, 24 juin 2025 (GLOBE NEWSWIRE) -- Bitget, principale bourse de cryptomonnaies et société Web3, a officiellement rejoint le portail indien Sahyog, une interface clé mise en place sous l’égide du Centre indien de coordination de la lutte contre la …